The University Clinical Center Tuzla (UKC Tuzla) has significantly advanced its radiotherapy capabilities with the acquisition of a modern brachytherapy device for the Clinic for Oncology and Radiotherapy. This major investment will particularly benefit oncology patients facing complex diagnoses by providing access to more precise and effective treatment options.
Brachytherapy is an advanced form of radiotherapy in which a radioactive source is placed directly into or near the tumor. This technique allows for the delivery of a high dose of radiation to the cancerous tissue while minimizing exposure to surrounding healthy organs. It is commonly used in the treatment of prostate, cervical, and breast cancers.
The procurement of the new device was made possible through a partnership between UKC Tuzla and the International Atomic Energy Agency (IAEA). The total value of the delivered equipment is €750,000, fully funded by the IAEA. This contribution marks a significant step forward in improving oncology care not only in Tuzla Canton but also across the broader region.
In addition to the equipment, the IAEA will provide continuous supply of radioactive iridium sources, which are essential for performing brachytherapy, for the next five years. This ensures the long-term sustainability of the service.
The introduction of brachytherapy at UKC Tuzla offers patients a more targeted and localized form of treatment, increasing the chances of recovery while reducing side effects. This initiative underscores a strong commitment to advancing healthcare services and supporting individuals in their fight against cancer.
